Nutritional considerations in patients with cystic fibrosis

Expert Review of Respiratory Medicine

Volumn 4, Issue 1, 2010, Pages 47-56

  Munck, Anne ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Cystic fibrosis; Energy intake; Fat soluble vitamins; Growth; Lung function; Neonatal screening; Nutrition; Pancreatic enzyme replacement therapy; Polyunsaturated fatty acid

Indexed keywords

25 HYDROXYVITAMIN D; ALPHA TOCOPHEROL; PANCREAS ENZYME; PLACEBO; POLYUNSATURATED FATTY ACID; RETINOL; TRIACYLGLYCEROL LIPASE; TRIZYTEK; UNCLASSIFIED DRUG; VITAMIN K GROUP; ZENTASE;

ANTIOXIDANT ACTIVITY; BODY MASS; CALORIC INTAKE; CHILD GROWTH; COGNITION; CYSTIC FIBROSIS; DIET SUPPLEMENTATION; DRUG MECHANISM; DRUG MEGADOSE; EARLY INTERVENTION; ENZYME RELEASE; ENZYME REPLACEMENT; FATTY ACID METABOLISM; FORCED EXPIRATORY VOLUME; HUMAN; INFLAMMATION; LOW FAT DIET; LUNG FUNCTION; MATERNAL NUTRITION; NEWBORN SCREENING; NUTRITIONAL ASSESSMENT; NUTRITIONAL REQUIREMENT; NUTRITIONAL STATUS; PATIENT MONITORING; RECOMMENDED DRUG DOSE; REVIEW; SURVIVAL RATE; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

EID: 77951647546     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.09.66     Document Type: Review

References (104)

1. Bell SC, Bowerman AM, Nixon LE et al. Metabolic and infammatory responses to pulmonary exacerbations in adults with cystic fbrosis. Eur. J. Clin. Invest. 30(6), 553-559 (2000).
2. Bell SC, Saunders MJ, Elborn JS, Shale DJ. Resting energy expenditure and oxygen cost of breathing in patients with cystic fbrosis. Thorax 51(2), 126-131 (1996).
3. Fried M, Durie P, Tsui LC et al. The cystic fbrosis gene and resting energy expenditure. J. Pediatr. 119(6), 913-916 (1991).
4. Littlewood JM, Wolfe SP, Conway SP. Diagnosis and treatment of intestinal malabsorption in cystic fbrosis. Pediatr. Pulmonol. 41(1), 35-49 (2006).
5. White H, Wolfe SP, Morton A, Conway SP, Brownlee KB. Nutritional intake and status in children with cystic fbrosis: does age matter? J. Pediatr. Gastroenterol. Nutr. 44(1), 116-123 (2007).
6. Cystic Fibrosis Foundation Patients Registry annual data report 2007. Bethesda, MD, USA (2007).
7. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fbrosis mortality and survival in the UK: 1947-2003. Eur. Respir. J. 29, 522-526 (2007).
8. O'Sullivan BP, Freedman SD. Cystic fbrosis. Lancet 373(9678), 1891-1904 (2009).
9. Stern M, Wiedemann B, Wenzlaff P. From registry to quality management: the German cystic fbrosis quality assessment project 1995-2006. Eur. Respir. J. 31(1), 29-35 (2008).
10. Lai HJ, Shoff SM. Classifcation of malnutrition in cystic fbrosis: implications for evaluating and benchmarking clinical practice performance. Am. J. Clin. Nutr. 88(1), 161-166 (2008).
11. Konstan MW, Butler SM, Wohl ME et al.; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Growth and nutritional indexes in early life predict pulmonary function in cystic fbrosis. J. Pediatr. 142(6), 624-630 (2003).
12. Peterson ML, Jacobs DR, Milla CE. Longitudinal changes in growth parameters are correlated with changes in pulmonary function in children with cystic fbrosis. Pediatrics 112(3), 588-592 (2003).
13. Shoff SM, Ahn HY, Davis L, Lai H; Wisconsin CF Neonatal Screening Group. Temporal associations among energy intake, plasma linoleic acid, and growth improvement in response to treatment initiation after diagnosis of cystic fbrosis. Pediatrics 117(2), 391-400 (2006).
14. Farrell PM, Kosorok MR, Laxova A et al. Nutritional benefts of neonatal screening for cystic fbrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N. Engl. J. Med. 337(14), 963-969 (1997).
15. Farrell PM, Lai HJ, Li Z et al. Evidence on improved outcomes with early diagnosis of cystic fbrosis through neonatal screening: enough is enough! J. Pediatr. 147(3 Suppl.), S30-S36 (2005).
16. Koscik RL, Farrell PM, Kosorok MR et al. Cognitive function of children with cystic fbrosis: deleterious effect of early malnutrition. Pediatrics 113(6), 1549-1558 (2004).
17. Koscik RL, Lai HJ, Laxova A et al. Preventing early, prolonged vitamin E defciency: an opportunity for better cognitive outcomes via early diagnosis through neonatal screening. J. Pediatr. 147(3 Suppl.), S51-S56 (2005).
18. Sims EJ, Clark A, McCormick J, Mehta G, Connett G, Mehta A; United Kingdom Cystic Fibrosis Database Steering Committee. Cystic fbrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy. Pediatrics 119(1), 19-28 (2007).
19. Accurso FJ, Sontag MK, Wagener JS. Complications associated with symptomatic diagnosis in infants with cystic fbrosis. J. Pediatr. 147(3 Suppl.), S37-S41 (2005).
20. Castellani C. Evidence for newborn screening for cystic fbrosis. Paediatr. Respir. Rev. 4(4), 278-284 (2003).
21. Lai HJ, Cheng Y, Farrell PM. The survival advantage of patients with cystic fbrosis diagnosed through neonatal screening: evidence from the United States Cystic Fibrosis Foundation registry data. J. Pediatr. 147(3 Suppl.), S57-S63 (2005).
22. Balfour-Lynn IM. Newborn screening for cystic fbrosis: evidence for beneft. Arch. Dis. Child. 93(1), 7-10 (2008).
23. Southern KW, Munck A, Pollitt R et al.; ECFS CF Neonatal Screening Working Group. A survey of newborn screening for cystic fbrosis in Europe. J. Cyst. Fibros. 6(1), 57-65 (2007). (Pubitemid 46029890)
24. Wilfond BS, Gollust SE. Policy issues for expanding newborn screening programs: the cystic fbrosis newborn screening experience in the United States. J. Pediatr. 46(5), 668-674 (2005).
25. Wilcken B. Newborn screening for cystic fbrosis: techniques and strategies. J. Inherit. Metab. Dis. 30(4), 537-543 (2007). (Pubitemid 47377049)
26. Kerem E, Reisman J, Corey et al. Prediction of mortality in patients with cystic fbrosis. N. Engl. J. Med. 326, 1187-1191 (1994).
27. Milla CE. Nutrition and lung disease in cystic fbrosis. Clin. Chest Med. 28, 319-330 (2007).
28. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fbrosis in Boston and Toronto. J. Clin. Epidemiol. 41(6), 583-591 (1988).
29. Lai HC, Corey M, FitzSimmons S, Kosorok MR, Farrell PM. Comparison of growth status of patients with cystic fbrosis between the United States and Canada. Am. J. Clin. Nutr. 69(3), 531-538 (1999).
30. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fbrosis. J. Pediatr. Gastroenterol. Nutr. 35(3), 246-259 (2002).
31. Sinaasappel M, Stern M, Littlewood J et al. Nutrition in patients with cystic fbrosis: a European Consensus. J. Cyst. Fibros. 1(2), 51-75 (2002).
32. Assael BM, Casazza G, Iansa P, Volpi S, Milani S. Growth and long-term lung function in cystic fbrosis: a longitudinal study of patients diagnosed by neonatal screening. Pediatr. Pulmonol. 44(3), 209-215 (2009).
33. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H; Clinical Practice Guidelines on Growth and Nutrition Subcommittee; Ad Hoc Working Group. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fbrosis and pancreatic insuffciency: results of a systematic review. J. Am. Diet Assoc. 108(5), 832-839 (2008).
34. Lai HJ, Shoff SM, Farrell PM; Wisconsin Cystic Fibrosis Neonatal Screening Group. Recovery of birth weight Z score within 2 years of diagnosis is positively associated with pulmonary status at 6 years of age in children with cystic fbrosis. Pediatrics 123(2), 714-722 (2009).
35. Poustie VJ, Watling RM, Ashby D, Smyth RL. Reliability of percentage ideal weight for height. Arch. Dis. Child. 83(2), 183-184 (2000).
36. Zhang Z, Lai HJ. Comparison of the use of body mass index percentiles and percentage of ideal body weight to screen for malnutrition in children with cystic fbrosis. Am. J. Clin. Nutr. 80(4), 982-991 (2004).
37. Lai HJ. Classifcation of nutritional status in cystic fbrosis. Curr. Opin. Pulm. Med. 12(6), 422-427 (2006).
38. Wiedemann B, Paul KD, Stern M, Wagner TO, Hirche TO; German CFQA Group. Evaluation of body mass index percentiles for assessment of malnutrition in children with cystic fbrosis. Eur. J. Clin. Nutr. 61(6), 759-768 (2007).
39. McDonald C. Validation of a nutrition risk screning tool for children and adolescents with cystcic fbrosis ages 2-20 years. J. Pediatr. Gastroenterol. Nutr. 46(4), 438-446 (2007).
40. Edenborough FP, Borgo G, Knoop C et al.; European Cystic Fibrosis Society. Guidelines for the management of pregnancy in women with cystic fbrosis. J. Cyst. Fibros. 7(Suppl. 1), S2-S32 (2008).
41. Colombo C, Costantini D, Zazzeron L et al. Benefts of breastfeeding in cystic fbrosis: a single-centre follow-up survey. Acta Paediatr. 96(8), 1228-1232 (2007).
42. Shearer JE, Bryon M. The nature and prevalence of eating disorders and eating disturbance in adolescents with cystic fbrosis. J. R. Soc. Med. 97(Suppl. 44), 36-42 (2004).
43. Sermet-Gaudelus I, Souberbielle JC, Ruiz JC et al. Low bone mineral density in young children with cystic fbrosis. Am. J. Respir. Crit. Care Med. 175(9), 951-957 (2007).
44. Aris RM, Merkel PA, Bachrach LK et al. Guide to bone health and disease in cystic fbrosis. J. Clin. Endocrinol. Metab. 90(3), 1888-1896 (2005).
45. Rolon MA, Benali K, Munck A et al. Cystic fbrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr. 90(8), 860-867 (2001).
46. White H, Pollard K, Etherington C et al. Nutritional decline in cystic fbrosis related diabetes: effect of intensive intervention. J. Cyst. Fibros. 8(3), 179-180 (2009).
47. O'Riordan SM, Robinson PD, Donaghue KC, Moran A; Clinical Practice Consensus. Management of cystic fbrosis-related diabetes. Pediatr. Diabetes 9(4), 338-344 (2008).
48. Smyth R, Walters S. Oral calorie supplements for cystic fbrosis. Cochrane Database Syst. Rev. 2, CD000406 (2000).
49. Kalnins D, Corey M, Ellis L, Pencharz PB, Tullis E, Durie PR. Failure of conventional strategies to improve nutritional status in malnourished adolescents and adults with cystic fbrosis. J. Pediatr. 147(3), 399-401 (2005).
50. Poustie VJ, Russell JE, Watling RM, Ashby D, Smyth RL; CALICO Trial Collaborative Group. Oral protein energy supplements for children with cystic fbrosis: CALICO multicentre randomised controlled trial. Br. Med. J. 332(7542), 632-636 (2006).
51. Stark LJ. Can nutrition counselling be more behavioural? Lessons learned from dietary management of cystic fbrosis. Proc. Nutr. Soc. 62(4), 793-799 (2003).
52. Conway SP, Morton A, Wolfe S. Enteral tube feeding for cystic fbrosis. Cochrane Database Syst. Rev. 2, CD001198 (2008).
53. Milla CE, Warwick WJ. Risk of death in cystic fbrosis patients with severely compromised lung function. Chest 113(5), 1230-1234 (1998).
54. Steinkamp G, Wiedemann B. Relationship between nutritional status and lung function in cystic fbrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 57(7), 596-601 (2002).
55. Oliver MR, Heine RG, Ng CH, Volders E, Olinsky A. Factors affecting clinical outcome in gastrostomy-fed children with cystic fbrosis. Pediatr. Pulmonol. 37(4), 324-329 (2004).
56. Efrati O, Mei-Zahav M, Rivlin J et al. Long term nutritional rehabilitation by gastrostomy in Israeli patients with cystic fbrosis: clinical outcome in advanced pulmonary disease. J. Pediatr. Gastroenterol. Nutr. 42(2), 222-228 (2006).
57. Nasr SZ, Drury D. Appetite stimulants use in cystic fbrosis. Pediatr. Pulmonol. 43(3), 209-219 (2008).
58. Davis PB. Cystic fbrosis since 1938. Am. J. Respir. Crit. Care Med. 173(5), 475-482 (2006).
59. Ratjen F, Döring G. Cystic fbrosis. Lancet 361(9358), 681-689 (2003).
60. Borowitz D, Baker SS, Duffy L et al. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fbrosis. J. Pediatr. 145(3), 322-326 (2004).
61. Daftary A, Acton J, Heubi J, Amin R. Fecal elastase-1: utility in pancreatic function in cystic fbrosis. J. Cyst. Fibros. 5(2), 71-76 (2006).
62. Borowitz D, Lin R, Baker SS. Comparison of monoclonal and polyclonal ELISAs for fecal elastase in patients with cystic fbrosis and pancreatic insuffciency. J. Pediatr. Gastroenterol. Nutr. 44(2), 219-223 (2007).
63. Kalnins D, Durie PR, Pencharz P. Nutritional management of cystic fbrosis patients. Curr. Opin. Clin. Nutr. Metab. Care 10(3), 348-354 (2007).
64. Walkowiak J, Nousia-Arvanitakis S, Agguridaki C et al. Longitudinal follow-up of exocrine pancreatic function in pancreatic suffcient cystic fbrosis patients using the fecal elastase-1 test. J. Pediatr. Gastroenterol. Nutr. 36(4), 474-478 (2003).
65. Weintraub A, Blau H, Mussaff H et al. Exocrine pancreatic function testing in patients with cystic fbrosis and pancreatic suffciency: a correlation study. J. Pediatr. Gastroenterol. Nutr. 48(3), 306-310 (2009).
66. Domínguez-Muñoz JE, Iglesias-García J, Iglesias-Rey M, Vilariño-Insua M. Optimising the therapy of exocrine pancreatic insuffciency by the association of a proton pump inhibitor to enteric coated pancreatic extracts. Gut 55(7), 1056-1057 (2006).
67. Proesmans M, De Boeck K. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fbrosis patients treated with high dose pancreatic enzymes. Eur J. Pediatr. 162(11), 760-763 (2003).
68. Dodge J. Pancreatic enzyme therapy in cystic fbrosis. Expert Rev. Resp. Med. 2(6), 681-683 (2008).
69. Smyth RL, Ashby D, O'Hea U et al. Fibrosing colonopathy in cystic fbrosis: results of a case-control study. Lancet 346(8985), 1247-1251 (1995).
70. FitzSimmons SC, Burkhart GA, Borowitz D et al. High-dose pancreatic-enzyme supplements and fbrosing colonopathy in children with cystic fbrosis. N. Engl. J. Med. 336(18), 1283-1289 (1997).
71. Baker SS, Borowitz D, Duffy L, Fitzpatrick L, Gyamf J, Baker RD. Pancreatic enzyme therapy and clinical outcomes in patients with cystic fbrosis. J. Pediatr. 146(2), 189-193 (2005).
72. Borowitz D, Durie PR, Clarke LL et al. Gastrointestinal outcomes and confounders in cystic fbrosis. J. Pediatr. Gastroenterol. Nutr. 41(3), 273-285 (2005).
73. Heubi JE. Pancreatic enzyme-replacement therapy in CF: considerations for the USA. Expert Rev. Resp. Med. 2(5), 589-596 (2008).
74. Borowitz D, Goss CH, Limauro S et al. Study of a novel pancreatic enzyme replacement therapy in pancreatic insuffcient subjects with cystic fbrosis. J. Pediatr. 149(5), 658-662 (2006).
75. Brady MS, Garson JL, Krug SK et al. An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fbrosis: a prospective, randomized study. J. Am. Diet. Assoc. 106(8), 1181-1186 (2006).
76. Wooldridge JL, Heubi JE, Amaro-Galvez R et al. EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fbrosis and pancreatic insuffciency. J. Cyst.Fibros. 8(6), 405-417 (2010).
77. Strandvik B, Hansson L, Hernell O et al. Recombinant human bile salt-stimulates lipase improves lipid uptake and reduces the pancreatic enzyme supplementation in patients with cystic fbrosis. Pediatr. Pulmonol. (Suppl. 27), 333 (2004).
78. Lenoir G, Dubray C, Chiron C et al. Recombinant gastric lipase (RGL) for the treatment of fat malabsorption. Pediatr. Pulmonol. (Suppl. 31), 306 (2008).
79. Maqbool A, Stallings VA. Update on fat-soluble vitamins in cystic fbrosis. Curr. Opin. Pulm. Med. 14(6), 574-581 (2008).
80. Hakim F, Kerem E, Rivlin J et al. Vitamins A and E and pulmonary exacerbations in patients with cystic fbrosis. J. Pediatr. Gastroenterol. Nutr. 45(3), 347-353 (2007).
81. Greer RM, Buntain HM, Lewindon PJ et al. Vitamin A levels in patients with CF are infuenced by the infammatory response. J. Cyst. Fibros. 3(3), 143-149 (2004).
82. Maqbool A, Graham-Maar RC, Schall JI, Zemel BS, Stallings VA. Vitamin A intake and elevated serum retinol levels in children and young adults with cystic fbrosis. J. Cyst. Fibros. 7(2), 137-141 (2008).
83. Tanumihardjo SA. Assessing vitamin A status: past, present and future. J. Nutr. 134(1), S290-S293 (2004).
84. Huang SH, Schall JI, Zemel BS, Stallings VA. Vitamin E status in children with cystic fbrosis and pancreatic insuffciency. J. Pediatr. 148(4), 556-559 (2006).
85. Papas K, Kalbfeisch J, Mohon R. Bioavailability of a novel, water-soluble vitamin E formulation in malabsorbing patients. Dig. Dis. Sci. 52(2), 347-352 (2007).
86. Jacquemin E, Hermeziu B, Kibleur Y et al. Bioavailability of oral vitamin E formulations in adult volunteers and children with chronic cholestasis or cystic fbrosis. J. Clin. Pharm. Ther. 34(5), 515-522 (2009).
87. Christen S, Woodall AA, Shigenaga MK, Southwell-Keely PT, Duncan MW, Ames BN. g-tocopherol traps mutagenic electrophiles such as NO(X) and complements a-tocopherol: physiological implications. Proc. Natl Acad. Sci. USA 94(7), 3217-3222 (1997).
88. Nicolaidou P, Stavrinadis I, Loukou I et al. The effect of vitamin K supplementation on biochemical markers of bone formation in children and adolescents with cystic fbrosis. Eur. J. Pediatr. 165(8), 540-545 (2006).
89. Conway SP, Wolfe SP, Brownlee KG et al. Vitamin K status among children with cystic fbrosis and its relationship to bone mineral density and bone turnover. Pediatrics 115(5), 1325-1331 (2005).
90. Urquhart DS, Fitzpatrick M, Cope J, Jaffe A. Vitamin K prescribing patterns and bone health surveillance in UK children with cystic fbrosis. J. Hum. Nutr. Diet 20(6), 605-610 (2007).
91. Rovner AJ, Stallings VA, Schall JI, Leonard MB, Zemel BS. Vitamin D insuffciency in children, adolescents, and young adults with cystic fbrosis despite routine oral supplementation. Am. J. Clin. Nutr. 86(6), 1694-1699 (2007).
92. Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin D and pulmonary function in the third national health and nutrition examination survey. Chest 128(6), 3792-3798 (2005).
93. Holick MF. Vitamin D defciency. N Engl J. Med. 357(3), 266-281 (2007).
94. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am. J. Clin. Nutr. 84(4), 694-697 (2006).
95. Strandvik B. Fatty acid metabolism in cystic fbrosis. N. Engl. J. Med. 350(6), 605-607 (2004).
96. Strandvik B, Gronowitz E, Enlund F, Martinsson T, Wahlström J. Essential fatty acid defciency in relation to genotype in patients with cystic fbrosis. J. Pediatr. 139(5), 650-655 (2001).
97. Harper TB, Chase HP, Henson PM. Essential fatty acid defciency in the rabbit as a model of nutritional impairment in cystic fbrosis: in vitro and in vivo effects on lung defense mechanisms. Am. Rev. Respir. Dis. 126(3), 540-547 (1982).
98. Craig-Schmidt MC, Faircloth SA, Teer PA, Weete JD, Wu CY. The essential fatty acid defcient chicken as a model for cystic fbrosis. Am. J. Clin. Nutr. 44(6), 816-824 (1986).
99. -/-) mice. Proc. Natl Acad. Sci. USA 96(24), 13995-14000 (1999).
100. Freedman SD, Blanco PG, Zaman MM et al Association of cystic fbrosis with abnormalities in fatty acid metabolism. N. Engl. J. Med. 350(6), 560-569 (2004).
101. -/- mice and the effect of docosahexaenoic acid. J. Appl. Physiol. 92(5), 2169-2176 (2002).
102. McKarney C, Everard M, N'Diaye T. Omega-3 fatty acids (from fsh oils) for cystic fbrosis. Cochrane Database Syst. Rev. 4, CD002201 (2007).
103. Panchaud A, Sauty A, Kernen Y et al. Biological effects of a dietary omega-3 polyunsaturated fatty acids in cystic fbrosis patients: a randomized, crossover placebo-controlled trial. Clin. Nutr. 25(3), 418-427 (2006).
104. Henderson WR, Astley SJ, McCready MM et al. Oral absorption of omega-3 fatty acids in patients with cystic fbrosis who have pancreatic insuffciency and in healthy control subjects. J. Pediatr. 124(3), 400-408 (1994).